Front. Mol. Neurosci. Frontiers in Molecular Neuroscience Front. Mol. Neurosci. 1662-5099 Frontiers Media S.A. 10.3389/fnmol.2019.00068 Neuroscience Mini Review Impaired Redox Signaling in Huntington’s Disease: Therapeutic Implications Paul Bindu D. 1 * Snyder Solomon H. 1 2 3 1The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States 2Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States 3Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Edited by: Daniela De Zio, Danish Cancer Society, Denmark

Reviewed by: Dan Lindholm, University of Helsinki, Finland; Mauro Cozzolino, Istituto di Farmacologia Traslazionale (IFT), Italy

 *Correspondence: Bindu D. Paul, bpaul8@jhmi.edu 19 03 2019 2019 12 68 29 12 2018 04 03 2019 Copyright © 2019 Paul and Snyder. 2019 Paul and Snyder

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Huntington’s disease (HD) is a neurodegenerative disease triggered by expansion of polyglutamine repeats in the protein huntingtin. Mutant huntingtin (mHtt) aggregates and elicits toxicity by multiple mechanisms which range from dysregulated transcription to disturbances in several metabolic pathways in both the brain and peripheral tissues. Hallmarks of HD include elevated oxidative stress and imbalanced redox signaling. Disruption of antioxidant defense mechanisms, involving antioxidant molecules and enzymes involved in scavenging or reversing oxidative damage, have been linked to the pathophysiology of HD. In addition, mitochondrial function is compromised in HD leading to impaired bioenergetics and elevated production of free radicals in cells. However, the exact mechanisms linking redox imbalance to neurodegeneration are still elusive. This review will focus on the current understanding of aberrant redox homeostasis in HD and potential therapeutic interventions.

 Huntington’s disease oxidative stress redox signaling cysteine mitochondria U.S. Public Health Service10.13039/100007197 Introduction

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by expansion of CAG repeats in the gene huntingtin, htt, present on chromosome 4 (MacDonald et al., 1993). About 1 in 7500 individuals are affected by HD worldwide, and no satisfactory cure exists so far (Fisher and Hayden, 2014). HD primarily affects the corpus striatum of the brain and manifests as abnormal involuntary movements, motor and cognitive deficits (Bates et al., 2015; McColgan and Tabrizi, 2018). Once symptoms appear, median survival is about 18 years (Ross et al., 2014). The number of CAG repeats in mutant htt (mHtt) inversely correlates with the age of onset of disease (Illarioshkin et al., 1994; Brandt et al., 1996). Translation of the CAG repeats results in an abnormally long polyglutamine repeat at the N-terminal end of Htt. mHtt is proteolytically cleaved and the N-terminal fragments aggregate to form inclusion bodies, a characteristic feature of the disease, although its role in disease progression is debated (Arrasate and Finkbeiner, 2012). Immunostaining with antibodies against mHtt led to the discovery of intranuclear inclusions in mouse models and patient samples, a hallmark of the disease (Davies et al., 1997; DiFiglia et al., 1997). mHtt impacts multiple cellular processes ranging from transcriptional and translational regulation, mitochondrial function, DNA replication and repair to nucleocytoplasmic transport which leads to neurotoxicity (Gu et al., 1996; Luthi-Carter et al., 2002; Lu X.H. et al., 2014; Banez-Coronel et al., 2015; Grima et al., 2017; Maiuri et al., 2017).

A prominent feature of HD is elevated oxidative stress. Oxidative stress is usually defined as a balance of prooxidant-antioxidant tendencies favoring the former. However, with advances in the field, oxidative stress is more appropriately defined as a disruption of redox signaling (Jones, 2006). Physiological levels of oxidative stress may be important for cellular processes (eustress) but excess, uncontrolled oxidative stress may be deleterious (distress) (Sies et al., 2017). The brain is particularly vulnerable to damage induced by oxidative stress. The brain is amongst the most metabolically active organ in the body and accounts for about 20% of the oxygen consumed (Gadoth and Goebel, 2011). The lipid-rich composition of the brain with its suboptimal antioxidant defense mechanisms as compared to peripheral tissues makes it a target for free radical-induced damage (Floyd and Carney, 1992). Reactive oxygen, nitrogen and sulfur species (ROS, RNS, and RSS) can induce protein oxidation, lipid peroxidation and DNA damage (Sbodio et al., 2018b). As in HD, oxidative stress has been observed in other neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic lateral sclerosis (ALS) and Ataxias and is linked to pathogenesis (Sbodio et al., 2018b).

 Redox Imbalance and HD

Several studies have reported oxidative damage in cells and tissues from HD models and patient samples. Elevated markers of damage such as protein oxidation, lipid peroxidation, and DNA damage have been linked to HD. The damage could stem from a variety of abnormalities arising due to the toxic effects of mHtt (summarized in Figure 1).

Sources of oxidative stress in HD. Decreased levels of antioxidants, cysteine and ascorbate is observed in HD. The cysteine transporter, excitatory amino acid transporter 3 (EAAT3/EAAC1) is dysregulated in HD leading to decreased intake of cysteine. The uptake of the oxidized form of cysteine, cystine, mediated by the xc− system, composed of the light chain xCT, and the heavy chain 4F2hc, is also reduced, contributing to low cysteine levels. Ascorbate influx via the SVCT2 transporter is also limited in HD, which leads to reduced antioxidant defense in neurons. Deposition of transition metals such as iron (Fe) has been observed both in the cytoplasm and mitochondria, leading to elevated levels of free radicals which can damage cellular components. Mutant huntingtin (mHtt) aggregates both in the nucleus and cytoplasm affecting multiple cellular processes, which include mitochondrial function, autophagy and proteostasis, which leads to elevated oxidative stress. In the nucleus, mHtt sequesters or affects transcription factors, several of which are involved in regulation of antioxidant defense mechanisms, further contributing to redox imbalance in cells. mHtt also affects DNA repair processes, which results in error prone repair and damage.

 Deposition of Metal Ions

Metal ions such as iron (Fe), copper (Cu), manganese (Mn), and Zinc (Zn) serve as cofactors for a variety of enzymes and participate in processes such as electron transport, redox regulation, and oxygen transport among others. These metals are beneficial in trace amounts, but excess accumulation leads to several pathological conditions. Iron is redox active, existing in the ferrous (Fe2+) and ferric (Fe3+) states. The Fe2+ form participates in the Fenton reaction reacting with hydrogen peroxide (H2O2) to generate the highly reactive hydroxyl radical (.OH) and HO2, which can cause oxidative damage to cellular components. Elevated iron content has been observed in the basal ganglia in symptomatic and late stage HD (Bartzokis et al., 1999, 2007; Bartzokis and Tishler, 2000). Iron accumulates in both neurons and glia, and treatment with deferoxamine, an iron chelator, affords neuroprotection in the R6/2 mouse model of HD (Simmons et al., 2007; Chen et al., 2013). Conversely, iron supplementation in the diet of neonatal R6/2 mice promotes neurodegeneration in the R6/2 mice (Berggren et al., 2015). Neonatal iron supplementation resulted in iron accumulation in mitochondria due to the increased expression of the mitochondrial iron transporter mitoferrin 2 (Agrawal et al., 2018). In addition to iron, excess copper deposition also mediates neurodegeneration in HD (Dexter et al., 1992; Fox et al., 2007). Copper binds the N-terminal region of mHtt, promotes its aggregation and delays its clearance (Fox et al., 2011). Accordingly, therapies preventing the accumulation of these redox active metals may prove beneficial.

 Altered Levels of Antioxidant Molecules and Enzymes

Cells harbor an array of metabolites and molecules that counteract oxidative damage. These may be endogenously synthesized or obtained from the diet. Diminished levels of the antioxidants cysteine, glutathione (GSH), coenzyme Q10 (CoQ10) and ascorbate have been observed in HD and could potentiate disease progression (Andrich et al., 2004; Paul et al., 2014).

Vitamin C/Ascorbate

Vitamin C/ascorbate is a water soluble molecule and cofactor for several enzymatic processes, which regulates metabolism and protects neurons against oxidative stress (Padh, 1990; Castro et al., 2009). During neuronal activity, glutamate is taken up and ascorbate released by astrocytes, which is accumulated by neurons via a specific transporter, SVCT2 (Wilson et al., 2000; Castro et al., 2001). Neuronal ascorbate promotes utilization of lactate over glucose during synaptic activity and also modulates redox balance. The uptake of ascorbate was compromised in cell culture and R6/2 mouse models of HD due to impaired translocation of SVCT2 to the plasma membrane and these changes preceded mitochondrial dysfunction (Acuna et al., 2013). Supplementation of ascorbate reversed the deficits.

 Cysteine

Cysteine is a semi-essential amino acid which is synthesized endogenously as well as obtained from the diet. The availability of cysteine is the rate limiting step for glutathione biosynthesis. We have shown previously that cysteine metabolism is compromised in HD (Paul et al., 2014, 2018). Expression of the biosynthetic enzyme for cysteine, cystathionine γ-lyase (CSE) is drastically decreased in HD due to the sequestration of its transcription factor, specificity protein1 (SP1) by mHtt. SP1 regulates transcription of CSE during basal conditions. During stress, expression of CSE is controlled by the stress-responsive activating transcription factor 4 (ATF4). In HD cells, induction of ATF4 is also suboptimal leading to decreased CSE expression and cysteine biosynthesis during stress (Sbodio et al., 2016). Both the biosynthesis and uptake of cysteine and its oxidized form are impaired in HD. Activity of the neuronal cysteine transporter, EAAT3/EAAC1 is decreased in HD due to inhibition of its trafficking to the plasma membrane (Li et al., 2010). Cysteine exists as its oxidized form, cystine, in extracellular fluids and is taken up by the cystine transport system, xc− system, composed of the light-chain (xCT, encoded by the SLC7A11 gene and the heavy-chain subunit 4F2hc, encoded by the SLC3A2 gene) into cells, where the reducing atmosphere converts it to its monomeric, reduced form, cysteine. The activity of xCT is decreased in HD leading to suboptimal cystine metabolism (Frederick et al., 2014). This is not surprising, considering that ATF4 is one of the transcription factors for the transporter’s expression. Supplementing cysteine and its stable precursor, N-acetyl cysteine (NAC) in the diet of R6/2 mice alleviated some of the symptoms and delayed disease progression. Cysteine is also the substrate for the generation of hydrogen sulfide (H2S), a gaseous signaling molecule that participates in a myriad of physiological processes. Three enzymes, CSE, cystathionine β-synthase (CBS) and 3-mercaptopyruvate sulfur transferase (3-MST), utilize cysteine to generate H2S. H2S signals by sulfhydration also called persulfidation, wherein the reactive –SH group of a cysteine residue is converted to a persulfide or –SSH group (Mustafa et al., 2009). Sulfhydration regulates the activity of several proteins and thus modulates several signal transduction cascades (Paul and Snyder, 2012, 2015a,b, 2018). As cysteine metabolism and CSE expression are altered in HD, levels of H2S are diminished in HD. We demonstrated that upregulating the transsulfuration pathway to induce CSE expression and H2S production has therapeutic benefits (Sbodio et al., 2018a,c). Cysteine is utilized by cells to generate several sulfur containing molecules such as cystamine, taurine, lanthionine, homolanthionine, and coenzyme A. The metabolism of these molecules in HD remain to be investigated.

 Glutathione

Glutathione, a tripeptide composed of glutamate, cysteine and glycine, is a major antioxidant involved in maintenance of redox homeostasis in cells (Meister and Anderson, 1983). GSH metabolism is dysregulated in HD, which could contribute to the redox imbalance observed in HD. Plasma GSH levels are inversely correlated to caudate atrophy in HD patients (Pena-Sanchez et al., 2015). Decrease in GSH in the postmortem cortex of HD patients has also been observed (Beal et al., 1992). However, other studies have detected increased intracellular glutathione levels in cell culture HD models and increased GSH in cortical and striatal mitochondria of the R6/2 mouse model of HD, although this increase was not sufficient to alleviate the oxidative stress associated with the disease (Choo et al., 2005; Ribeiro et al., 2012), which could reflect differences in the systems utilized or compensatory mechanisms.

 Antioxidant Proteins and Pathways

In addition to small molecule antioxidants, cells are equipped with an array of proteins and enzymes which scavenge or neutralize reactive oxygen and nitrogen species. These include superoxide dismutases (SOD1), glutathione peroxidases (GPx), peroxiredoxins (PRDXs), and catalase (Sbodio et al., 2018b). The activities of GPx and SOD1, which act on lipid hydroperoxides and superoxide, were decreased in erythtocytes of HD patients (Chen et al., 2007). Cytosolic SOD1 activity was also decreased in the HD parietal cortex and putamen (Browne et al., 1997). Increasing the activity of GPx1, either by genetic or pharmacologic means in cell culture, yeast and Drosophila models of HD mitigated toxicity (Mason et al., 2013). In addition to effects on antioxidant enzymes, mHtt affects the activity of several transcription factors which regulate antioxidant defense and redox signaling pathways. For instance, as explained earlier, mHtt alters SP1 and ATF4 function, thereby affecting expression of CSE and cysteine metabolism (Paul and Snyder, 2014; Paul et al., 2014; Sbodio et al., 2016). Elevated oxidative stress perturbs the compensatory cytoprotective responses in HD. Our studies using a cell culture model of HD revealed that excessive oxidative stress perturbs signaling mediated by ATF4, a master regulator of amino acid homeostasis. Reduction of oxidative stress improves the response of ATF4 to stress stimuli (Sbodio et al., 2016). Nuclear factor erythroid 2-related factor (Nrf2), which orchestrates gene expression pathways which involved in redox balance and proteostasis (Kensler et al., 2007; Tsvetkov et al., 2013; Dinkova-Kostova et al., 2018) is another transcription factor influenced in HD. Blunted Nrf2 signaling was observed in cell culture models of HD (Jin et al., 2013; Rotblat et al., 2014). Thus, stimulation of Nrf2 signaling pathway may be beneficial in HD (Bresciani et al., 2017).

 Mitochondrial Dysfunction

In addition to compromised antioxidant defense as described in the previous section, mitochondrial dysfunction plays a central role in redox imbalance. Mitochondria are the predominant source of ROS and free radicals. Mitochondria are also sites of oxidative phosphorylation (OXPHOS) which is carried out by five multisubunit electron transport complexes (ETCs), designated complexes I–V. Electrons are transported from NADH to NADH coenzyme Q reductase (complex I) to coenzyme Q, which also receives electrons from succinate dehydrogenase (SDH/complex II). Coenzyme Q then relays the electrons to cytochrome C oxidase (complex IV) via complex III (cytochrome bc1). Complex IV reduces molecular oxygen to water using these electrons. Mitochondrial malfunction can lead to oxidative and nitrosative stress through several pathways.

Suboptimal Functioning of the Electron Transport Chain (ETC)

Mitochondrial malfunction in HD was first implied by nuclear magnetic resonance spectroscopy, which revealed increased lactate levels in the striatum and cortex of HD patients (Jenkins et al., 1993). Activities of complex II, III and IV are decreased in HD brains (Gu et al., 1996; Browne et al., 1997). During the process of respiration, the highly reactive O2•− is generated, especially by complexes I and III (Raha and Robinson, 2000; Murphy, 2009). Electron transport through the complexes is coupled to proton translocation via the mitochondrial inter membrane space, forming an electrochemical proton gradient (electromotive force) and a mitochondrial transmembrane potential (Δψm), necessary for generation of ATP. In HD, the transmembrane potential is perturbed, impacting mitochondrial bioenergetics (Carmo et al., 2018). The close proximity of the ETC to the mitochondrial genome makes it highly susceptible to oxidative and nitrosative damage. Oxidative DNA damage, as measured by levels of 8-hydroxy-2-deoxyguanosine (OH8dG), to mitochondrial DNA (mtDNA) occurs predominantly in the parietal region of the human HD brain, as opposed to the cerebellum or the frontal cortex with the medium spiny neurons (MSNs) accumulating the greatest damage (Polidori et al., 1999). Consistent with these findings, inhibition of complex II by 3-NPA induced HD-like symptoms and neurotoxicity (Beal et al., 1993). mHtt can affect multiple aspects of mitochondrial function which contribute to elevated oxidative stress (Figure 2).

Mitochondrial dysfunction in HD. Mutant huntingtin (mHtt) elicits mitochondrial dysfunction through several mechanisms. mHtt interacts with the outer mitochondrial membrane and could be responsible for several of the observed deficits. mHtt impacts the electron transport chain (ETC), leading to decreased generation of ATP and increased production of ROS such as superoxide (O2-∙). Increased levels of oxidants damage mitochondrial DNA and nuclear DNA which further compromise mitochondrial function to generate more ROS in a vicious cycle. mHtt also induces defects in Ca2+ homeostasis, increasing Ca2+ influx via the N-methyl-D-aspartate (NMDA) receptors and excitotoxicity. Increased Fe deposition is observed in HD, which can participate in the Fenton reaction to produce the highly reactive OH∙, which causes DNA damage. OH∙ react with nitric oxide (NO) to generate peroxynitrite (ONOO-), which causes nitrosative damage to cellular components. mHtt impairs the transcriptional activity of several transcription factors involved in mitochondrial maintenance and function. The expression of the peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC1-α) transcriptional coactivator, a regulator of mitochondrial biogenesis is diminished in HD by mHtt. mHtt affects the activity of the transcription factor cAMP response element binding protein (CREB) and other proteins such as TATA-box binding protein (TBP) and TBP-associated factor 4 (TAF4), comprising the transcription initiation complex to decrease PGC1-α expression. As PGC1-α has roles in redox homeostasis, its depletion results in oxidative distress. In addition to these effects, mHtt causes mitochondrial fragmentation, binding to the GTPase dynamin related protein 1 (Drp1, whose expression, along with Fis1 is increased in HD) and stimulating its activity to increase fission. Mitochondrial fusion is also impaired in HD due to decreased levels of the proteins involved in fusion, optic atrophy 1 (Opa1) and Mitofusins (Mfn1 and 2).

 Abnormal Ca<sup>2+</sup> Homeostasis

Mitochondrial Ca2+ is perturbed in HD, which impacts diverse mitochondrial dynamics (Kolobkova et al., 2017). mHtt interacts with the outer mitochondrial membrane and affects the mitochondrial permeability transition pore (mPTP), decreasing the Ca2+ threshold to trigger mPTP opening, and lowering ATP levels within the organelle (Choo et al., 2004). mHtt has also been shown to interact with Ca2+-binding proteins such as calmodulin; disruption of this interaction has proved beneficial (Bao et al., 1996; Dudek et al., 2010). Interaction of mHtt with type 1 inositol (1,4,5)-triphosphate receptor (InsP3R1), an intracellular Ca2+ release channel, has also been reported (Tang et al., 2003). Although Ca2+ has no direct effect on redox reactions, mitochondrial Ca2+ overload induces elevations in ROS levels which in turn cause mtDNA damage (Peng and Jou, 2010; Wang et al., 2013).

 Impaired Function of Transcription Factors and Proteins Involved in Mitochondrial Function

Mutant huntingtin interacts with and affects the function of a number of transcription factors involved in maintenance of mitochondrial function. For instance, mHtt binds to PPARγ coactivator 1α (PGC-1α), a regulator of several metabolic processes including mitochondrial respiration and biogenesis (Cui et al., 2006). PGC-1α also regulates a battery of proteins involved in antioxidant defense and suppresses the formation of ROS in cells (St-Pierre et al., 2006). In addition, mHtt associates with the PGC-1α promoter and interferes with the transcriptional activation functions of promoter-bound transcription factors, CREB and TAF4 leading to diminished PGC-1α expression, mitochondrial abnormalities, and elevated oxidative stress. Besides these processes, mHtt affects mitochondrial trafficking, fission and fusion, resulting in low ATP levels and impaired bioenergetics (Reddy and Shirendeb, 2012; Carmo et al., 2018). The mitochondrial network in cells is dynamic, undergoing fission and fusion to maintain morphology and function. mHtt interferes with the balance of fission and fusion. mHtt binds to dynamin-related protein 1 (Drp1), whose expression is increased in HD, and enhances its GTPase activity to increase mitochondrial fragmentation and distribution (Costa et al., 2010; Song et al., 2011). Furthermore, nitrosylation of Drp1, which increases its activity, has been reported in HD (Nakamura et al., 2010). In addition, expression of the adaptor protein mitochondrial fission 1 (Fis1) is elevated in HD. Mitochondrial fusion mediated by the proteins mitofusin 1 and 2 (Mfn 1 and 2) and the optic atrophy 1 (OPA1) is also affected, as revealed by decreased levels of these proteins in the striatum and cortex of HD patients (Shirendeb et al., 2011). Accordingly, specifically targeting mitochondrial fission and fusion processes may be beneficial (Yin et al., 2016).

 Autophagy

As discussed above, damaged mitochondria can further exacerbate oxidative stress hence their removal by autophagy can prevent further damage (Murphy, 2009). Autophagy is a conserved lysosomal degradation pathway which acts by clearance of damaged molecules and organelles and mobilizes cellular nutrients in response to several forms of stress (Klionsky and Emr, 2000; Kroemer et al., 2010; Bento et al., 2016; Leidal et al., 2018). Autophagy and oxidative stress have been linked in several studies. There are numerous reports on dysregulated autophagy in HD (Harding and Tong, 2018). Autophagy plays a vital role in maintaining healthy mitochondria in cells by mitochondrial-specific recycling termed mitophagy. Mitochondrial quality control in neurons is highly dependent on autophagy and plays a central role in neuronal bioenergetics (Batlevi and La Spada, 2011; Redmann et al., 2017). As mitochondrial metabolism generates free radicals, autophagic clearance of damaged mitochondria would limit the levels of oxidative and nitrosative damage (Giordano et al., 2014).

 Endoplasmic Reticulum Stress (ER Stress)

Another pathway whose dysregulation leads to elevated oxidative stress is the ER stress signaling cascade. The ER is essential for several cellular functions including but not limited to protein synthesis, folding, maturation, quality control, calcium homeostasis, and glucose metabolism (Almanza et al., 2019). Accumulation of misfolded proteins in the ER triggers a stress response termed the ER stress response, which is a characteristic feature of several neurodegenerative diseases involving protein misfolding and aggregation, such as HD (Hetz and Saxena, 2017). The ER also generates ROS during its normal functions. Expression of N-terminal huntingtin proteins with expanded polyglutamine repeats has been reported to induce cell death in neuronal PC6.3 cell lines that involves endoplasmic reticulum (ER) stress and inhibition of ER stress improved viability and decreased protein aggregation caused by mHtt (Reijonen et al., 2008). One of the proteins involved in the ER stress response is the transcription factor, nuclear factor-κB (NF-κB), which mediates anti-oxidant and anti-apoptotic signaling (Pahl and Baeuerle, 1995; Deng et al., 2004; Sen et al., 2012; Han and Kaufman, 2017). Overexpression of mutant huntingtin proteins in the PC6.3 cell lines results in diminished NF-κB expression and concomitant increase in oxidative stress, decrease in antioxidant levels and enhanced cell death (Reijonen et al., 2010). Accordingly drugs that target the NF-κB pathway may be beneficial in HD. For instance, PRE084, an agonist of the Sigma-1 receptor, Sig-1R, an ER resident chaperone protein, increases NF-κB expression and improves cell viability and mitigates the toxicity mediated by mutant huntingtin proteins in neuronal PC6.3 cells (Hyrskyluoto et al., 2013). Dysregulated NF-κB has also been reported in other studies using RNA-seq and network analysis, where activation has been reported (Miller et al., 2016; Al-Ramahi et al., 2018). Thus, it appears that stage-specific analysis with additional cell types would be necessary to obtain a comprehensive picture of the immune signaling axis in HD.

 Defective DNA Repair

Besides, the processes outlined above, defective DNA repair is linked to elevated oxidative stress and contributes to disease progression. Oxidative DNA damage as assessed by formation of 8-OHdG has been observed in both nuclear and mtDNA (Browne et al., 1997). The expanded CAG repeats in mHtt display both germline and somatic instability; the extent of oxidative damage positively correlates with the degree of expansion (Mangiarini et al., 1997; Kovtun et al., 2007). Expansion of the triplet repeats occurs during repair of DNA damage, especially the oxidized guanosine bases, a process relying on the DNA glycosylase OGG1. This base excision repair, BER, is error prone and leads to expansion of the polyglutamine repeats in a process involving single strand breaks and strand slippage. Expansion of the polyglutamine tract further induces oxidative damage and error-prone repair of the lesions, forming a vicious oxidative cycle (Kovtun et al., 2007). Another DNA repair pathway affected in HD involves the ataxia-telangectasia mutated (ATM) protein (Lu X.H. et al., 2014). ATM initiates repair and is activated during oxidative stress and upon DNA damage (Shiloh and Ziv, 2013). Excessive activation of ATM has been reported in HD; inhibiting its activity delays disease progression in mouse models of HD (Lu X.H. et al., 2014). The N terminal end of normal Htt acts as a sensor of ROS and has been shown to detach from the ER, get phosphorylated and translocate to the nucleus when a methionine residue (M8) is oxidized (DiGiovanni et al., 2016). Htt acts as a scaffolding protein for ATM at sites of DNA damage; the CAG repeats may affect the DNA repair process (Maiuri et al., 2017).

 Exploring Therapeutic Options in HD

A central feature of complex neurodegenerative diseases such as HD is elevated redox stress, which is intimately linked to disease progression. The current understanding of redox signaling and the intricate interplay between the various pathways involved in protection against oxidative and nitrosative stress is not complete. Whether elevated levels of ROS/RNS are the cause or consequence of disease is still not clear, however increased redox stress exacerbates neurodegeneration and blunts cytoprotective responses. Aberrant redox signaling has been observed in other complex disease states such as cancer. While cancer is associated with uncontrolled cell proliferation, neurodegeneration is characterized by premature cell death. Tumorigenesis and neurodegeneration appear to be at two ends of a homeostatic regulatory breakdown. Antioxidant defense mechanisms such as cysteine and glutathione synthesis are bolstered in cancers leading to reduced sensitivity to radio and chemotherapy, whereas the converse appears to operate in most neurodegenerative diseases (Benfeitas et al., 2017; Vucetic et al., 2017; Sbodio et al., 2018b). Thus, targeting cancer cells by increasing ROS levels have proved beneficial in several cancers (Trachootham et al., 2009; Wondrak, 2009; Ishimoto et al., 2011). In neurodegeneration associated with compromised redox homeostasis, diminishing ROS levels may afford therapeutic benefit. Although antioxidant supplementation has been beneficial in mouse models of HD (Table 1), human clinical trials using antioxidants have been largely unsuccessful in HD and other neurodegenerative diseases (Kim et al., 2015). Several factors may underlie the inefficacy of these antioxidants. Most antioxidants used cannot completely intercept or neutralize oxidant species, leading to a slow buildup of oxidative damage. The antioxidants used target only certain species of free radicals and oxidants; a single antioxidant cannot target all oxidant species. Antioxidant therapy can damage normal cellular processes such as autophagy (Underwood et al., 2010). Accordingly, antioxidants that do not negatively interact with normal cellular processes or have off-target effects may be desirable. Reversing or preventing oxidative damage as well as targeting cytoprotective pathways as a whole, as opposed to simple scavenging of oxidants, may afford greater protection against neurodegeneration. Development of non-cytotoxic drugs that possess multitarget, combinatorial selectivity may be more effective (Varshavsky, 1998). Another aspect which has been largely unexplored in HD is the complex interaction between soluble and cellular immune system components in neurodegeneration. In HD, analysis of redox signaling pathways as a function of disease progression is crucial, as end-stage analysis of tissues likely lack the cells of interest which may have already died. Moreover, population studies by themselves may not be sufficient, as individual variations and heterogeneity in redox pathways and genes that control them may affect the treatment outcome. Comprehensive analyses coupling genomics, transcriptomics, proteomics, metabolomics, and clinical data may reveal central hubs for therapeutic intervention. Such approaches are being pursued for cancer therapy and may have applications in HD (Bidkhori et al., 2018). The timing of intervention, the site of delivery and recycling of the antioxidant should also be considered to arrive at effective redox-active molecules. Development of therapies specific for the various reactive oxygen, nitrogen species and other free radicals, would facilitate a greater understanding of disease progression. Combination therapy involving antioxidant supplementation in conjunction with strategies that strengthen cellular antioxidant capacity may also be considered.

Molecules with antioxidant and neuroprotective effects in HD.

Antioxidant Systems tested Effects Reference
α-Lipoic acid R6/2 and N171-82Q mice3-NP model (rat) Improved survival.Normalized mitochondrial lipid composition, improved mitochondrial structure and mitigated cognitive impairment in 3-NP-treated animals. Andreassen et al., 2001Mehrotra et al., 2015
α-Tocopherol(vitamin E) HD patients3-Nitropropropionic acid (3-NP) model of HD (rat) Therapeutic effect on neurologic symptoms for early stage patients.Elevation of creatine kinase (CK) elicited by 3-NP in cytosol was prevented by a combination therapy of vitamin E and Coenzyme Q10 (CoQ10). Peyser et al., 1995Kasparova et al., 2006
L-Ascorbic acid (vitamin C) STHdhQ111 cells, R6/2 miceR6/2 miceSTHdhQ111 cells Modulates glucose uptake via GLUT3, which is compromised in HD.Attenuated the neurological motor signs and behavioral aspects of HD.Improves behavior related ascorbate release.Restored dysregulated amino acid homeostasis modulated by ATF4. Acuna et al., 2013Covarrubias-Pinto et al., 2015Rebec et al., 2003Rebec et al., 2006Sbodio et al., 2016
N-Acetyl cysteine (NAC) 3-NP model (rat)R6/2 miceR6/1 miceR6/1 mice Prevented mitochondrial dysfunction, neurobehavioral deficits, decreased oxidative stress.In combination with cysteine supplemented diet, NAC improved motor function, prevented striatal atrophy, and increased survival.Improves mitochondrial function and ameliorates behavioral deficits.Mediated an antidepressant effect. Restored glutamate homeostasis through system xc− Sandhir et al., 2012Paul et al., 2014Wright et al., 2015Wright et al., 2016
Anthocyanin R6/1 mice Modest effects on CAG repeat instability in the ears and cortex. Mollersen et al., 2016
Coenzyme Q10(CoQ10) R6/2 miceR6/2 mice, N171-82Q miceR6/2 mice3-Nitropropropionic acid (3-NP) model of HD (rat), R6/2 miceHD patients Increased survival, delayed motor deficits, weight loss, cerebral atrophy, and neuronal intranuclear inclusions.Combination therapy with the NMDA antagonist, remacemide decreased ventricular enlargement, and increased survival.Improved motor performance and grip strength, decreased weight loss, brain atrophy, huntingtin inclusions, and oxidative DNA damage in treated R6/2 mice.Combination therapy with creatine inhibited 3-NP-induced impairment of glutathione homeostasis, decreased lipid peroxidation and oxidative DNA damage. Improved motor function and survival in R6/2 mice.CoQ10 alone is not effective in human trials.Idebenone, an analog, did not significantly alter outcome. Ferrante et al., 2002Ferrante et al., 2002Smith et al., 2006Yang et al., 2009McGarry et al., 2017Brandt et al., 1996
Creatine Neural progenitor cellsHD patients Increases neural progenitor cell survival in HD.Slows down brain atrophy in premanifest HD.However, was not effective in a randomized controlled trial (CREST-E). Andres et al., 2016Bender and Klopstock, 2016Hersch et al., 2017
Curcumin 3-NP modelCAG140 KIDrosophila model of HD Prevented 3-NP-induced motor and cognitive impairment. Reduced oxidative stress and prevented decrease in succinate dehydrogenase activity.Decreases mutant Htt aggregates in the brain. Partial improvement of transcriptional deficits and behavioral improvement.Decreased photoreceptor neuron degeneration, reduced cell death, and ameliorated motor dysfunction. Kumar et al., 2007Hickey et al., 2012Chongtham and Agrawal, 2016
Cystamine R6/2 miceR6/2 mice, 3-NP model (mice)YAC128 mice3-NP model (mice, astrocyte, and mixed astrocyte-neuronal cell cultureDrosophila model of HDSTHdhQ111 cells Improved survival, reduced tremor, and abnormal movements and ameliorated weight loss.Increased forebrain cysteine and glutathione levels in R6/2 mice. Protected against 3-NP-induced striatal injury in mice.Prevented striatal neuronal loss, striatal volume loss and striatal neuronal atrophy.Induced Nrf2 and glutathione production.Improved longevity when fed both during larval and adult stages but did not prevent photoreceptor degeneration. When fed to adult flies expressing anti-htt intracellular antibody (intrabody), photoreceptor degeneration was suppressed but longevity effects were absent.Increased mutant cells viability when stressed and prevented ROS formation and increased antioxidant defense. Karpuj et al., 2002Fox et al., 2004Van Raamsdonk et al., 2005Calkins et al., 2010Bortvedt et al., 2010Ribeiro et al., 2013
Deferoxamine R6/2 mice Improved motor phenotype. Chen et al., 2013
Dimethylfumarate R6/2 miceYAC128 mice Preserved neuronal morphology. Decreases weight loss and clasping phenotype. Induces the Nrf2 pathway, which maintains redox balance. Ellrichmann et al., 2011
Isoquercetin Neurons from C. elegans model (128Q) of HDMutant Htt mouse striatal (109Q) cells Suppressed the loss of touch response in 128Q worms.Prevented cell death caused by serum deprivation in the 109Q striatal neurons. Farina et al., 2017
Lycopene 3-NP model (rat) Improved mitochondrial function and decreased oxidative stress in 3-NP treated animals. Sandhir et al., 2010
Melatonin 3-NP model (rat)Htt ST14A cellsR6/2 mice Prevents toxicity induced by 3-NP. Decreases lipid peroxidation levels and protein carbonylation.Preserved mitochondrial membrane potential and inhibited cell death pathways in cells.Delays disease onset and mortality in R6/2 mice. Decreased activated caspase-9 and caspase-3 levels. Tunez et al., 2004Wang et al., 2011
Monensin STHdhQ111 cells Increased survival in response to cysteine deprivation and decreased oxidative stress. Increased the production of the neuroprotective gasotransmitter, hydrogen sulfide. Sbodio et al., 2018a
Nicotinamide 3-NP model (rat) Improved motor function and decreased oxidative stress markers (malondialdehyde, nitrites) and increased antioxidant enzyme (glutathione) levels. Decreased lactate dehydrogenase and prevented striatal neuronal death. Sidhu et al., 2018
Pridopidine YAC128 miceHD patients Reversed aberrant gene expression, behavioral deficits, and activated cytoprotective pathways.Activated sigma 1 receptor to reduce oxidative stress and increased BDNF levels. Possible slowing of clinical progression. Garcia-Miralles et al., 2017; Kusko et al., 2018Reilmann et al., 2019
Quercetin 3-NP model (rat) Ameliorated mitochondrial dysfunction, oxidative stress, and neurobehavioral deficits in rats. Sandhir and Mehrotra, 2013; Amanzadeh et al., 2019
Resveratrol Human HD lymphoblastsYAC 128 mice Increased mtDNA copies and mitochondrial-related transcription factors (TFAM and nuclear PGC1α).Increased expression of mitochondrial electron transport chain proteins. Improved motor function. Naia et al., 2017
Rutin 3-NP model (rat) Prevented motor and cognitive deficits induced by 3-NP. Prevented striatal degeneration. Decreased oxidative stress. Suganya and Sumathi, 2017
Selenium 3-NP model (rat)N171-82Q mice Bis selenide prevented weight loss and motor dysfunction. Decreased oxidative stress.Improved motor function, decreased loss of brain weight, decreased mutant huntingtin aggregation and oxidized glutathione levels. Bortolatto et al., 2013Lu Z. et al., 2014
Sulforaphane Neuroprogenitor cell line, HC2S2 harboring EGFP tagged htt exon 1 (28Q, 74Q)3-NP model (mice)Quinolinic acid (QA) model (rat) Enhanced mHtt degradation and reduced mHtt cytotoxicity.Stimulated the Keap1-Nrf2-ARE Pathway and Inhibited the MAPKs and NF-κB Pathways to mitigate neurotoxicity.Prevented mitochondrial dysfunction elicited by QA. Liu et al., 2014Jang and Cho, 2016Luis-Garcia et al., 2017
Trehalose N2A cells harboring tNhtt-60Q–EGFP, tNhtt-150Q–EGFP; R6/2 miceCOS-7 and SK-N-SH cells expressing (EGFP-HDQ74); R6/2 miceHuman HD fibroblasts Decreased polyglutamine aggregates in cerebrum and liver, improved motor dysfunction and extended lifespan.Induced autophagy and cleared aggregates.Prevented increase in oxidative stress, ubiquitinated proteins, huntingtin and activated caspase-3 induced by inhibition of proteasome. Tanaka et al., 2004Sarkar et al., 2007Fernandez-Estevez et al., 2014
XJB-5-1-131 HdhQ (150/150) miceR6/2 mice Diminished oxidative damage to mitochondrial DNA, preserved mitochondrial DNA copy number and function, suppressed motor decline and weight loss, improved neuronal survival.Also effective in animals with well-developed pathology. Promoted weight gain, inhibited neuronal death, decreased neuronal oxidative damage, prevented motor dysfunction or improved it, and reduced a graying phenotype in treated HdhQ (150/150) animals.Reduced weight loss, and improved the motor and temperature regulation deficits, especially in male mice male R6/2 mice. No effect on the lifespan. Slowed somatic expansion at 90 days, and reduced inclusion density. Xun et al., 2012Polyzos et al., 2016Polyzos et al., 2018
The therapeutic outcome of antioxidant molecules or those mitigating oxidative stress, in cell culture, animal models, and human patients are listed. Concluding Remarks

It is becoming increasingly evident that our knowledge of redox signaling and its bearing on the origin of these complex diseases is not complete. Repurposing/repositioning/recycling/reprofiling drugs, which have cytoprotective effects in the brain, may offer viable options to arrive at safe and effective drugs for these complex diseases. Such strategies are currently actively investigated for cancers and neurodegeneration (Duraes et al., 2018; Turanli et al., 2018). Studies encompassing diverse genetic, epigenetic and environmental factors may facilitate development of specific therapies targeting redox diseases.

 Author Contributions

BP conceptualized the theme of the review. BP and SS wrote the manuscript.

 Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding. This work was supported by grants from the US Public Health Service (MH18501 and DA000266 to SS).

 References Acuna A. I. Esparza M. Kramm C. Beltran F. A. Parra A. V. Cepeda C. (2013). A failure in energy metabolism and antioxidant uptake precede symptoms of Huntington’s disease in mice. Nat. Commun. 4:2917. 10.1038/ncomms3917 24336051 Agrawal S. Fox J. Thyagarajan B. Fox J. H. (2018). Brain mitochondrial iron accumulates in Huntington’s disease, mediates mitochondrial dysfunction, and can be removed pharmacologically. Free Radic. Biol. Med. 120 317–329. 10.1016/j.freeradbiomed.2018.04.002 29625173 Almanza A. Carlesso A. Chintha C. Creedican S. Doultsinos D. Leuzzi B. (2019). Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications. FEBS J. 286 241–278. 10.1111/febs.14608 30027602 Al-Ramahi I. Lu B. Di Paola S. Pang K. de Haro M. Peluso I. (2018). High-throughput functional analysis distinguishes pathogenic, nonpathogenic, and compensatory transcriptional changes in neurodegeneration. Cell Syst. 7 28.e4–40.e4. 10.1016/j.cels.2018.05.010 29936182 Amanzadeh E. Esmaeili A. Rahgozar S. Nourbakhshnia M. (2019). Application of quercetin in neurological disorders: from nutrition to nanomedicine. Rev. Neurosci. 10.1515/revneuro-2018-0080 [Epub ahead of print]. 30753166 Andreassen O. A. Ferrante R. J. Dedeoglu A. Beal M. F. (2001). Lipoic acid improves survival in transgenic mouse models of Huntington’s disease. Neuroreport 12 3371–3373. 10.1097/00001756-200110290-00044 11711888 Andres R. H. Wallimann T. Widmer H. R. (2016). Creatine supplementation improves neural progenitor cell survival in Huntington’s disease. Brain Circ. 2 133–137. 10.4103/2394-8108.192519 30276289 Andrich J. Saft C. Gerlach M. Schneider B. Arz A. Kuhn W. (2004). Coenzyme Q10 serum levels in Huntington’s disease. J. Neural. Trans. Suppl. 68 111–116. 10.1007/978-3-7091-0579-5_13 Arrasate M. Finkbeiner S. (2012). Protein aggregates in Huntington’s disease. Exp. Neurol. 238 1–11. 10.1016/j.expneurol.2011.12.013 22200539 Banez-Coronel M. Ayhan F. Tarabochia A. D. Zu T. Perez B. A. Tusi S. K. (2015). RAN translation in huntington disease. Neuron 88 667–677. 10.1016/j.neuron.2015.10.038 26590344 Bao J. Sharp A. H. Wagster M. V. Becher M. Schilling G. Ross C. A. (1996). Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc. Natl. Acad. Sci. U.S.A. 93 5037–5042. 10.1073/pnas.93.10.5037 8643525 Bartzokis G. Cummings J. Perlman S. Hance D. B. Mintz J. (1999). Increased basal ganglia iron levels in Huntington disease. Arch. Neurol. 56 569–574. 10.1001/archneur.56.5.569 Bartzokis G. Lu P. H. Tishler T. A. Fong S. M. Oluwadara B. Finn J. P. (2007). Myelin breakdown and iron changes in Huntington’s disease: pathogenesis and treatment implications. Neurochem. Res. 32 1655–1664. 10.1007/s11064-007-9352-7 17484051 Bartzokis G. Tishler T. A. (2000). MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer’s and Huntingon’s disease. Cell Mol. Biol. 46 821–833. 10875443 Bates G. P. Dorsey R. Gusella J. F. Hayden M. R. Kay C. Leavitt B. R. (2015). Huntington disease. Nat. Rev. Dis. Prim. 1:15005. 10.1038/nrdp.2015.5 27188817 Batlevi Y. La Spada A. R. (2011). Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging. Neurobiol. Dis. 43 46–51. 10.1016/j.nbd.2010.09.009 20887789 Beal M. F. Brouillet E. Jenkins B. G. Ferrante R. J. Kowall N. W. Miller J. M. (1993). Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13 4181–4192. 10.1523/JNEUROSCI.13-10-04181.1993 Beal M. F. Matson W. R. Storey E. Milbury P. Ryan E. A. Ogawa T. (1992). Kynurenic acid concentrations are reduced in Huntington’s disease cerebral cortex. J. Neurol. Sci. 108 80–87. 10.1016/0022-510X(92)90191-M Bender A. Klopstock T. (2016). Creatine for neuroprotection in neurodegenerative disease: end of story? Amino Acids 48 1929–1940. 10.1007/s00726-015-2165-0 26748651 Benfeitas R. Uhlen M. Nielsen J. Mardinoglu A. (2017). New challenges to study heterogeneity in cancer redox metabolism. Front. Cell Dev. Biol. 5:65. 10.3389/fcell.2017.00065 28744456 Bento C. F. Renna M. Ghislat G. Puri C. Ashkenazi A. Vicinanza M. (2016). Mammalian autophagy: how does it work? Annu. Rev. Biochem. 85 685–713. 10.1146/annurev-biochem-060815-014556 26865532 Berggren K. L. Chen J. Fox J. Miller J. Dodds L. Dugas B. (2015). Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington’s disease. Redox. Biol. 4 363–374. 10.1016/j.redox.2015.02.002 25703232 Bidkhori G. Benfeitas R. Klevstig M. Zhang C. Nielsen J. Uhlen M. (2018). Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc. Natl. Acad. Sci. U.S.A. 115 E11874–E11883. 10.1073/pnas.1807305115 30482855 Bortolatto C. F. Jesse C. R. Wilhelm E. A. Chagas P. M. Nogueira C. W. (2013). Organoselenium bis selenide attenuates 3-nitropropionic acid-induced neurotoxicity in rats. Neurotox. Res. 23 214–224. 10.1007/s12640-012-9336-5 22739838 Bortvedt S. F. McLear J. A. Messer A. Ahern-Rindell A. J. Wolfgang W. J. (2010). Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington’s disease. Neurobiol. Dis. 40 130–134. 10.1016/j.nbd.2010.04.007 20399860 Brandt J. Bylsma F. W. Gross R. Stine O. C. Ranen N. Ross C. A. (1996). Trinucleotide repeat length and clinical progression in Huntington’s disease. Neurology 46 527–531. 10.1212/WNL.46.2.527 Bresciani A. Missineo A. Gallo M. Cerretani M. Fezzardi P. Tomei L. (2017). Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1). Arch. Biochem. Biophys. 631 31–41. 10.1016/j.abb.2017.08.003 28801166 Browne S. E. Bowling A. C. MacGarvey U. Baik M. J. Berger S. C. Muqit M. M. (1997). Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41 646–653. 10.1002/ana.410410514 9153527 Calkins M. J. Townsend J. A. Johnson D. A. Johnson J. A. (2010). Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription. Exp. Neurol. 224 307–317. 10.1016/j.expneurol.2010.04.008 20406637 Carmo C. Naia L. Lopes C. Rego A. C. (2018). Mitochondrial dysfunction in huntington’s disease. Adv. Exp. Med. Biol. 1049 59–83. 10.1007/978-3-319-71779-1_3 29427098 Castro M. Caprile T. Astuya A. Millan C. Reinicke K. Vera J. C. (2001). High-affinity sodium-vitamin C co-transporters (SVCT) expression in embryonic mouse neurons. J. Neurochem. 78 815–823. 10.1046/j.1471-4159.2001.00461.x 11520902 Castro M. A. Beltran F. A. Brauchi S. Concha I. I. (2009). A metabolic switch in brain: glucose and lactate metabolism modulation by ascorbic acid. J. Neurochem. 110 423–440. 10.1111/j.1471-4159.2009.06151.x 19457103 Chen C. M. Wu Y. R. Cheng M. L. Liu J. L. Lee Y. M. Lee P. W. (2007). Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients. Biochem. Biophys. Res. Commun. 359 335–340. 10.1016/j.bbrc.2007.05.093 17543886 Chen J. Marks E. Lai B. Zhang Z. Duce J. A. Lam L. Q. (2013). Iron accumulates in huntington’s disease neurons: protection by deferoxamine. PLoS One 8:e77023. 10.1371/journal.pone.0077023 24146952 Chongtham A. Agrawal N. (2016). Curcumin modulates cell death and is protective in huntington’s disease model. Sci. Rep. 6:18736. 10.1038/srep18736 26728250 Choo Y. S. Johnson G. V. MacDonald M. Detloff P. J. Lesort M. (2004). Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13 1407–1420. 10.1093/hmg/ddh162 15163634 Choo Y. S. Mao Z. Johnson G. V. Lesort M. (2005). Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington’s disease mouse model. Neurosci. Lett. 386 63–68. 10.1016/j.neulet.2005.05.065 15993538 Costa V. Giacomello M. Hudec R. Lopreiato R. Ermak G. Lim D. (2010). Mitochondrial fission and cristae disruption increase the response of cell models of Huntington’s disease to apoptotic stimuli. EMBO Mol. Med. 2 490–503. 10.1002/emmm.201000102 21069748 Covarrubias-Pinto A. Moll P. Solis-Maldonado M. Acuna A. I. Riveros A. Miro M. P. (2015). Beyond the redox imbalance: oxidative stress contributes to an impaired GLUT3 modulation in Huntington’s disease. Free Radic. Biol. Med. 89 1085–1096. 10.1016/j.freeradbiomed.2015.09.024 26456058 Cui L. Jeong H. Borovecki F. Parkhurst C. N. Tanese N. Krainc D. (2006). Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127 59–69. 10.1016/j.cell.2006.09.015 17018277 Davies S. W. Turmaine M. Cozens B. A. DiFiglia M. Sharp A. H. Ross C. A. (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 537–548. 10.1016/S0092-8674(00)80513-9 9267033 Deng J. Lu P. D. Zhang Y. Scheuner D. Kaufman R. J. Sonenberg N. (2004). Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol. Cell Biol. 24 10161–10168. 10.1128/MCB.24.23.10161-10168.2004 15542827 Dexter D. T. Jenner P. Schapira A. H. Marsden C. D. (1992). Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. the royal kings and queens parkinson’s disease research group. Ann. Neurol. 32 S94–S100. 10.1002/ana.410320716 1510387 DiFiglia M. Sapp E. Chase K. O. Davies S. W. Bates G. P. Vonsattel J. P. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 1990–1993. 10.1126/science.277.5334.1990 9302293 DiGiovanni L. F. Mocle A. J. Xia J. Truant R. (2016). Huntingtin N17 domain is a reactive oxygen species sensor regulating huntingtin phosphorylation and localization. Hum. Mol. Genet. 25 3937–3945. 10.1093/hmg/ddw234 27466181 Dinkova-Kostova A. T. Kostov R. V. Kazantsev A. G. (2018). The role of Nrf2 signaling in counteracting neurodegenerative diseases. FEBS J. 285 3576–3590. 10.1111/febs.14379 29323772 Dudek N. L. Dai Y. Muma N. A. (2010). Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin. Brain Pathol. 20 176–189. 10.1111/j.1750-3639.2008.00258.x 19338577 Duraes F. Pinto M. Sousa E. (2018). Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals 11:E44. 10.3390/ph11020044 29751602 Ellrichmann G. Petrasch-Parwez E. Lee D. H. Reick C. Arning L. Saft C. (2011). Efficacy of fumaric acid esters in the R6/2 and YAC128 models of huntington’s disease. PLoS One 6:e16172. 10.1371/journal.pone.0016172 21297955 Farina F. Lambert E. Commeau L. Lejeune F. X. Roudier N. Fonte C. (2017). The stress response factor daf-16/FOXO is required for multiple compound families to prolong the function of neurons with Huntington’s disease. Sci. Rep. 7:4014. 10.1038/s41598-017-04256-w 28638078 Fernandez-Estevez M. A. Casarejos M. J. Lopez Sendon J. Garcia Caldentey J. Ruiz C. Gomez A. (2014). Trehalose reverses cell malfunction in fibroblasts from normal and Huntington’s disease patients caused by proteosome inhibition. PLoS One 9:e90202. 10.1371/journal.pone.0090202 24587280 Ferrante R. J. Andreassen O. A. Dedeoglu A. Ferrante K. L. Jenkins B. G. Hersch S. M. (2002). Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease. J. Neurosci. 22 1592–1599. 10.1523/JNEUROSCI.22-05-01592.2002 Fisher E. R. Hayden M. R. (2014). Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov. Disord. 29 105–114. 10.1002/mds.25717 24151181 Floyd R. A. Carney J. M. (1992). Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann. Neurol. 32 S22–S27. 10.1002/ana.410320706 1510377 Fox J. H. Barber D. S. Singh B. Zucker B. Swindell M. K. Norflus F. (2004). Cystamine increases L-cysteine levels in Huntington’s disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J. Neurochem. 91 413–422. 10.1111/j.1471-4159.2004.02726.x 15447674 Fox J. H. Connor T. Stiles M. Kama J. Lu Z. Dorsey K. (2011). Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. J. Biol. Chem. 286 18320–18330. 10.1074/jbc.M110.199448 21454633 Fox J. H. Kama J. A. Lieberman G. Chopra R. Dorsey K. Chopra V. (2007). Mechanisms of copper ion mediated Huntington’s disease progression. PLoS One 2:e334. 10.1371/journal.pone.0000334 17396163 Frederick N. M. Bertho J. Patel K. K. Petr G. T. Bakradze E. Smith S. B. (2014). Dysregulation of system xc(-) expression induced by mutant huntingtin in a striatal neuronal cell line and in R6/2 mice. Neurochem. Int. 76 59–69. 10.1016/j.neuint.2014.06.017 25004085 Gadoth N. Goebel H. H. (2011). Oxidative Stress and Free Radical Damage in Neurology. New York, NY: Humana Press. 10.1007/978-1-60327-514-9 Garcia-Miralles M. Geva M. Tan J. Y. Yusof N. Cha Y. Kusko R. (2017). Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight 2:95665. 10.1172/jci.insight.95665 29212949 Giordano S. Darley-Usmar V. Zhang J. (2014). Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol. 2 82–90. 10.1016/j.redox.2013.12.013 24494187 Grima J. C. Daigle J. G. Arbez N. Cunningham K. C. Zhang K. Ochaba J. (2017). Mutant huntingtin disrupts the nuclear pore complex. Neuron 94 93.e6–107e6. 10.1016/j.neuron.2017.03.023 28384479 Gu M. Gash M. T. Mann V. M. Javoy-Agid F. Cooper J. M. Schapira A. H. (1996). Mitochondrial defect in Huntington’s disease caudate nucleus. Ann. Neurol. 39 385–389. 10.1002/ana.410390317 8602759 Han J. Kaufman R. J. (2017). Physiological/pathological ramifications of transcription factors in the unfolded protein response. Genes Dev. 31 1417–1438. 10.1101/gad.297374.117 28860159 Harding R. J. Tong Y. F. (2018). Proteostasis in Huntington’s disease: disease mechanisms and therapeutic opportunities. Acta Pharmacol. Sin. 39 754–769. 10.1038/aps.2018.11 29620053 Hersch S. M. Schifitto G. Oakes D. Bredlau A. L. Meyers C. M. Nahin R. (2017). The CREST-E study of creatine for huntington disease: a randomized controlled trial. Neurology 89 594–601. 10.1212/WNL.0000000000004209 28701493 Hetz C. Saxena S. (2017). ER stress and the unfolded protein response in neurodegeneration. Nat. Rev. Neurol. 13 477–491. 10.1038/nrneurol.2017.99 28731040 Hickey M. A. Zhu C. Medvedeva V. Lerner R. P. Patassini S. Franich N. R. (2012). Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington’s disease. Mol. Neurodegener. 7:12. 10.1186/1750-1326-7-12 22475209 Hyrskyluoto A. Pulli I. Tornqvist K. Ho T. H. Korhonen L. Lindholm D. (2013). Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-kappaB pathway. Cell Death Dis. 4:e646. 10.1038/cddis.2013.170 23703391 Illarioshkin S. N. Igarashi S. Onodera O. Markova E. D. Nikolskaya N. N. Tanaka H. (1994). Trinucleotide repeat length and rate of progression of Huntington’s disease. Ann. Neurol. 36 630–635. 10.1002/ana.410360412 7944295 Ishimoto T. Nagano O. Yae T. Tamada M. Motohara T. Oshima H. (2011). CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19 387–400. 10.1016/j.ccr.2011.01.038 21397861 Jang M. Cho I. H. (2016). Sulforaphane ameliorates 3-nitropropionic acid-induced striatal toxicity by activating the keap1-Nrf2-ARE pathway and inhibiting the MAPKs and NF-kappaB pathways. Mol. Neurobiol. 53 2619–2635. 10.1007/s12035-015-9230-2 26096705 Jenkins B. G. Koroshetz W. J. Beal M. F. Rosen B. R. (1993). Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized 1H NMR spectroscopy. Neurology 43 2689–2695. 10.1212/WNL.43.12.2689 Jin Y. N. Yu Y. V. Gundemir S. Jo C. Cui M. Tieu K. (2013). Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. PLoS One 8:e57932. 10.1371/journal.pone.0057932 23469253 Jones D. P. (2006). Redefining oxidative stress. Antioxid. Redox. Signal. 8 1865–1879. 10.1089/ars.2006.8.1865 16987039 Karpuj M. V. Becher M. W. Springer J. E. Chabas D. Youssef S. Pedotti R. (2002). Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8 143–149. 10.1038/nm0202-143 11821898 Kasparova S. Sumbalova Z. Bystricky P. Kucharska J. Liptaj T. Mlynarik V. (2006). Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington’s disease. Neurochem. Int. 48 93–99. 10.1016/j.neuint.2005.09.002 16290265 Kensler T. W. Wakabayashi N. Biswal S. (2007). Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47 89–116. 10.1146/annurev.pharmtox.46.120604.141046 16968214 Kim G. H. Kim J. E. Rhie S. J. Yoon S. (2015). The role of oxidative stress in neurodegenerative diseases. Exp. Neurobiol. 24 325–340. 10.5607/en.2015.24.4.325 26713080 Klionsky D. J. Emr S. D. (2000). Autophagy as a regulated pathway of cellular degradation. Science 290 1717–1721. 10.1126/science.290.5497.1717 Kolobkova Y. A. Vigont V. A. Shalygin A. V. Kaznacheyeva E. V. (2017). Huntington’s disease: calcium dyshomeostasis and pathology models. Acta Nat. 9 34–46. Kovtun I. V. Liu Y. Bjoras M. Klungland A. Wilson S. H. McMurray C. T. (2007). OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature 447 447–452. 10.1038/nature05778 17450122 Kroemer G. Marino G. Levine B. (2010). Autophagy and the integrated stress response. Mol. Cell 40 280–293. 10.1016/j.molcel.2010.09.023 20965422 Kumar P. Padi S. S. Naidu P. S. Kumar A. (2007). Possible neuroprotective mechanisms of curcumin in attenuating 3-nitropropionic acid-induced neurotoxicity. Methods Find. Exp. Clin. Pharmacol. 29 19–25. 10.1358/mf.2007.29.1.1063492 17344940 Kusko R. Dreymann J. Ross J. Cha Y. Escalante-Chong R. Garcia-Miralles M. (2018). Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Mol. Neurodegener. 13:25. 10.1186/s13024-018-0259-3 29783994 Leidal A. M. Levine B. Debnath J. (2018). Autophagy and the cell biology of age-related disease. Nat. Cell Biol. 20 1338–1348. 10.1038/s41556-018-0235-8 30482941 Li X. Valencia A. Sapp E. Masso N. Alexander J. Reeves P. (2010). Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington’s disease. J. Neurosci. 30 4552–4561. 10.1523/JNEUROSCI.5865-09.2010 20357106 Liu Y. Hettinger C. L. Zhang D. Rezvani K. Wang X. Wang H. (2014). Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington’s disease. J. Neurochem. 129 539–547. 10.1111/jnc.12647 24383989 Lu X. H. Mattis V. B. Wang N. Al-Ramahi I. van den Berg N. Fratantoni S. A. (2014). Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington’s disease. Sci. Transl. Med. 6:268ra178. 10.1126/scitranslmed.3010523 25540325 Lu Z. Marks E. Chen J. Moline J. Barrows L. Raisbeck M. (2014). Altered selenium status in Huntington’s disease: neuroprotection by selenite in the N171-82Q mouse model. Neurobiol. Dis. 71 34–42. 10.1016/j.nbd.2014.06.022 25014023 Luis-Garcia E. R. Limon-Pacheco J. H. Serrano-Garcia N. Hernandez-Perez A. D. Pedraza-Chaverri J. Orozco-Ibarra M. (2017). Sulforaphane prevents quinolinic acid-induced mitochondrial dysfunction in rat striatum. J. Biochem. Mol. Toxicol. 31:e21837. 10.1002/jbt.21837 27589053 Luthi-Carter R. Hanson S. A. Strand A. D. Bergstrom D. A. Chun W. Peters N. L. (2002). Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 11 1911–1926. 10.1093/hmg/11.17.1911 12165554 MacDonald M. E. Ambrose C. M. Duyao M. P. Myers R. H. Lin C. Srinidhi L. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The huntington’s disease collaborative research group. Cell 72 971–983. 10.1016/0092-8674(93)90585-E Maiuri T. Mocle A. J. Hung C. L. Xia J. van Roon-Mom W. M. Truant R. (2017). Huntingtin is a scaffolding protein in the ATM oxidative DNA damage response complex. Hum. Mol. Genet. 26 395–406. 10.1093/hmg/ddw395 28017939 Mangiarini L. Sathasivam K. Mahal A. Mott R. Seller M. Bates G. P. (1997). Instability of highly expanded CAG repeats in mice transgenic for the Huntington’s disease mutation. Nat. Genet. 15 197–200. 10.1038/ng0297-197 9020849 Mason R. P. Casu M. Butler N. Breda C. Campesan S. Clapp J. (2013). Glutathione peroxidase activity is neuroprotective in models of Huntington’s disease. Nat. Genet. 45 1249–1254. 10.1038/ng.2732 23974869 McColgan P. Tabrizi S. J. (2018). Huntington’s disease: a clinical review. Eur. J. Neurol. 25 24–34. 10.1111/ene.13413 28817209 McGarry A. McDermott M. Kieburtz K. de Blieck E. A. Beal F. Marder K. (2017). A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 88 152–159. 10.1212/WNL.0000000000003478 27913695 Mehrotra A. Sood A. Sandhir R. (2015). Mitochondrial modulators improve lipid composition and attenuate memory deficits in experimental model of Huntington’s disease. Mol. Cell Biochem. 410 281–292. 10.1007/s11010-015-2561-5 26374445 Meister A. Anderson M. E. (1983). Glutathione. Annu. Rev. Biochem. 52 711–760. 10.1146/annurev.bi.52.070183.003431 Miller J. R. Lo K. K. Andre R. Hensman Moss D. J. Trager U. Stone T. C. (2016). RNA-Seq of Huntington’s disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Hum. Mol. Genet. 25 2893–2904. 10.1093/hmg/ddw142 27170315 Mollersen L.Rowe A. D. Bjolgerud A. Holm I. Tveteras L. (2016). Effects of anthocyanins on CAG repeat instability and behaviour in huntington’s disease R6/1 Mice. PLoS Curr. 8. 10.1371/currents.hd.58d04209ab6d5de0844db7ef5628ff67 27540492 Murphy M. P. (2009). How mitochondria produce reactive oxygen species. Biochem. J. 417 1–13. 10.1042/BJ20081386 19061483 Mustafa A. K. Gadalla M. M. Sen N. Kim S. Mu W. Gazi S. K. (2009). H2S signals through protein S-sulfhydration. Sci. Signal. 2:ra72. 10.1126/scisignal.2000464 19903941 Naia L. Rosenstock T. R. Oliveira A. M. Oliveira-Sousa S. I. Caldeira G. L. Carmo C. (2017). Comparative mitochondrial-based protective effects of resveratrol and nicotinamide in huntington’s disease models. Mol. Neurobiol. 54 5385–5399. 10.1007/s12035-016-0048-3 27590140 Nakamura T. Cieplak P. Cho D. H. Godzik A. Lipton S. A. (2010). S-nitrosylation of Drp1 links excessive mitochondrial fission to neuronal injury in neurodegeneration. Mitochondrion 10 573–578. 10.1016/j.mito.2010.04.007 20447471 Padh H. (1990). Cellular functions of ascorbic acid. Biochem. Cell Biol. 68 1166–1173. 10.1139/o90-173 Pahl H. L. Baeuerle P. A. (1995). A novel signal transduction pathway from the endoplasmic reticulum to the nucleus is mediated by transcription factor NF-kappa B. EMBO J. 14 2580–2588. 10.1002/j.1460-2075.1995.tb07256.x Paul B. D. Sbodio J. I. Snyder S. H. (2018). Cysteine metabolism in neuronal redox homeostasis. Trends Pharmacol. Sci. 39 513–524. 10.1016/j.tips.2018.02.007 29530337 Paul B. D. Sbodio J. I. Xu R. Vandiver M. S. Cha J. Y. Snowman A. M. (2014). Cystathionine gamma-lyase deficiency mediates neurodegeneration in Huntington’s disease. Nature 509 96–100. 10.1038/nature13136 24670645 Paul B. D. Snyder S. H. (2012). H(2)S signalling through protein sulfhydration and beyond. Nat. Rev. Mol. Cell Biol. 13 499–507. 10.1038/nrm3391 22781905 Paul B. D. Snyder S. H. (2014). Neurodegeneration in Huntington’s disease involves loss of cystathionine gamma-lyase. Cell Cycle 13 2491–2493. 10.4161/15384101.2014.950538 25486189 Paul B. D. Snyder S. H. (2015a). H2S: a novel gasotransmitter that signals by sulfhydration. Trends Biochem. Sci. 40 687–700. 10.1016/j.tibs.2015.08.007 26439534 Paul B. D. Snyder S. H. (2015b). Modes of physiologic H2S signaling in the brain and peripheral tissues. Antioxid. Redox. Signal. 22 411–423. 10.1089/ars.2014.5917 24684551 Paul B. D. Snyder S. H. (2018). Gasotransmitter hydrogen sulfide signaling in neuronal health and disease. Biochem. Pharmacol. 149 101–109. 10.1016/j.bcp.2017.11.019 29203369 Pena-Sanchez M. Riveron-Forment G. Zaldivar-Vaillant T. Soto-Lavastida A. Borrero-Sanchez J. Lara-Fernandez G. (2015). Association of status redox with demographic, clinical and imaging parameters in patients with Huntington’s disease. Clin. Biochem. 48 1258–1263. 10.1016/j.clinbiochem.2015.06.014 26210848 Peng T. I. Jou M. J. (2010). Oxidative stress caused by mitochondrial calcium overload. Ann. N. Y. Acad. Sci. 1201 183–188. 10.1111/j.1749-6632.2010.05634.x 20649555 Peyser C. E. Folstein M. Chase G. A. Starkstein S. Brandt J. Cockrell J. R. (1995). Trial of d-alpha-tocopherol in Huntington’s disease. Am. J. Psychiatry 152 1771–1775. 10.1176/ajp.152.12.1771 8526244 Polidori M. C. Mecocci P. Browne S. E. Senin U. Beal M. F. (1999). Oxidative damage to mitochondrial DNA in huntington’s disease parietal cortex. Neurosci. Lett. 272 53–56. 10.1016/S0304-3940(99)00578-9 Polyzos A. Holt A. Brown C. Cosme C. Wipf P. Gomez-Marin A. (2016). Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes. Hum. Mol. Genet. 25 1792–1802. 10.1093/hmg/ddw051 26908614 Polyzos A. A. Wood N. I. Williams P. Wipf P. Morton A. J. McMurray C. T. (2018). XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington’s disease is age- and sex- dependent. PLoS One 13:e0194580. 10.1371/journal.pone.0194580 29630611 Raha S. Robinson B. H. (2000). Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. Sci. 25 502–508. 10.1016/S0968-0004(00)01674-1 Rebec G. V. Barton S. J. Marseilles A. M. Collins K. (2003). Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuroreport 14 1263–1265. 10.1097/01.wnr.0000081868.45938.12 12824772 Rebec G. V. Conroy S. K. Barton S. J. (2006). Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment. Neuroscience 137 327–336. 10.1016/j.neuroscience.2005.08.062 16257492 Reddy P. H. Shirendeb U. P. (2012). Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington’s disease. Biochim. Biophys. Acta 1822 101–110. 10.1016/j.bbadis.2011.10.016 22080977 Redmann M. Benavides G. A. Berryhill T. F. Wani W. Y. Ouyang X. Johnson M. S. (2017). Inhibition of autophagy with bafilomycin and chloroquine decreases mitochondrial quality and bioenergetic function in primary neurons. Redox. Biol. 11 73–81. 10.1016/j.redox.2016.11.004 27889640 Reijonen S. Kukkonen J. P. Hyrskyluoto A. Kivinen J. Kairisalo M. Takei N. (2010). Downregulation of NF-kappaB signaling by mutant huntingtin proteins induces oxidative stress and cell death. Cell Mol. Life Sci. 67 1929–1941. 10.1007/s00018-010-0305-y 20232225 Reijonen S. Putkonen N. Norremolle A. Lindholm D. Korhonen L. (2008). Inhibition of endoplasmic reticulum stress counteracts neuronal cell death and protein aggregation caused by N-terminal mutant huntingtin proteins. Exp. Cell Res. 314 950–960. 10.1016/j.yexcr.2007.12.025 18255062 Reilmann R. McGarry A. Grachev I. D. Savola J. M. Borowsky B. Eyal E. (2019). Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 18 165–176. 10.1016/S1474-4422(18)30391-0 Ribeiro M. Rosenstock T. R. Cunha-Oliveira T. Ferreira I. L. Oliveira C. R. Rego A. C. (2012). Glutathione redox cycle dysregulation in Huntington’s disease knock-in striatal cells. Free Radic. Biol. Med. 53 1857–1867. 10.1016/j.freeradbiomed.2012.09.004 22982598 Ribeiro M. Silva A. C. Rodrigues J. Naia L. Rego A. C. (2013). Oxidizing effects of exogenous stressors in Huntington’s disease knock-in striatal cells–protective effect of cystamine and creatine. Toxicol. Sci. 136 487–499. 10.1093/toxsci/kft199 24008831 Ross C. A. Aylward E. H. Wild E. J. Langbehn D. R. Long J. D. Warner J. H. (2014). Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 10 204–216. 10.1038/nrneurol.2014.24 24614516 Rotblat B. Southwell A. L. Ehrnhoefer D. E. Skotte N. H. Metzler M. Franciosi S. (2014). HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proc. Natl. Acad. Sci. U.S.A. 111 3032–3037. 10.1073/pnas.1314421111 24516159 Sandhir R. Mehrotra A. (2013). Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: implications in Huntington’s disease. Biochim. Biophys. Acta 1832 421–430. 10.1016/j.bbadis.2012.11.018 23220257 Sandhir R. Mehrotra A. Kamboj S. S. (2010). Lycopene prevents 3-nitropropionic acid-induced mitochondrial oxidative stress and dysfunctions in nervous system. Neurochem. Int. 57 579–587. 10.1016/j.neuint.2010.07.005 20643176 Sandhir R. Sood A. Mehrotra A. Kamboj S. S. (2012). N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington’s disease. Neurodegener. Dis. 9 145–157. 10.1159/000334273 22327485 Sarkar S. Davies J. E. Huang Z. Tunnacliffe A. Rubinsztein D. C. (2007). Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 282 5641–5652. 10.1074/jbc.M609532200 17182613 Sbodio J. I. Snyder S. H. Paul B. D. (2016). Transcriptional control of amino acid homeostasis is disrupted in Huntington’s disease. Proc. Natl. Acad. Sci. U.S.A. 113 8843–8848. 10.1073/pnas.1608264113 27436896 Sbodio J. I. Snyder S. H. Paul B. D. (2018a). Golgi stress response reprograms cysteine metabolism to confer cytoprotection in Huntington’s disease. Proc. Natl. Acad. Sci. U.S.A. 115 780–785. 10.1073/pnas.1717877115 29317536 Sbodio J. I. Snyder S. H. Paul B. D. (2018b). Redox mechanisms in neurodegeneration: from disease outcomes to therapeutic opportunities. Antioxid. Redox. Signal. 30 1450–1499. 10.1089/ars.2017.7321 29634350 Sbodio J. I. Snyder S. H. Paul B. D. (2018c). Regulators of the transsulfuration pathway. Br. J. Pharmacol. 176 583–593. 10.1111/bph.14446 30007014 Sen N. Paul B. D. Gadalla M. M. Mustafa A. K. Sen T. Xu R. (2012). Hydrogen sulfide-linked sulfhydration of NF-kappaB mediates its antiapoptotic actions. Mol. Cell 45 13–24. 10.1016/j.molcel.2011.10.021 22244329 Shiloh Y. Ziv Y. (2013). The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14 197–210. 10.1038/nrm3546 23486281 Shirendeb U. Reddy A. P. Manczak M. Calkins M. J. Mao P. Tagle D. A. (2011). Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage. Hum. Mol. Genet. 20 1438–1455. 10.1093/hmg/ddr024 21257639 Sidhu A. Diwan V. Kaur H. Bhateja D. Singh C. K. Sharma S. (2018). Nicotinamide reverses behavioral impairments and provides neuroprotection in 3-nitropropionic acid induced animal model ofHuntington’s disease: implication of oxidative stress- poly(ADP- ribose) polymerase pathway. Metab. Brain Dis. 33 1911–1921. 10.1007/s11011-018-0297-0 30054774 Sies H. Berndt C. Jones D. P. (2017). Oxidative stress. Annu. Rev. Biochem. 86 715–748. 10.1146/annurev-biochem-061516-045037 28441057 Simmons D. A. Casale M. Alcon B. Pham N. Narayan N. Lynch G. (2007). Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington’s disease. Glia 55 1074–1084. 10.1002/glia.20526 17551926 Smith K. M. Matson S. Matson W. R. Cormier K. Del Signore S. J. Hagerty S. W. (2006). Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington’s disease mice. Biochim. Biophys. Acta 1762 616–626. 10.1016/j.bbadis.2006.03.004 16647250 Song W. Chen J. Petrilli A. Liot G. Klinglmayr E. Zhou Y. (2011). Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med. 17 377–382. 10.1038/nm.2313 21336284 St-Pierre J. Drori S. Uldry M. Silvaggi J. M. Rhee J. Jager S. (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127 397–408. 10.1016/j.cell.2006.09.024 17055439 Suganya S. N. Sumathi T. (2017). Effect of rutin against a mitochondrial toxin, 3-nitropropionicacid induced biochemical, behavioral and histological alterations-a pilot study on Huntington’s disease model in rats. Metab. Brain Dis. 32 471–481. 10.1007/s11011-016-9929-4 27928694 Tanaka M. Machida Y. Niu S. Ikeda T. Jana N. R. Doi H. (2004). Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10 148–154. 10.1038/nm985 14730359 Tang T. S. Tu H. Chan E. Y. Maximov A. Wang Z. Wellington C. L. (2003). Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39 227–239. 10.1016/S0896-6273(03)00366-0 12873381 Trachootham D. Alexandre J. Huang P. (2009). Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8 579–591. 10.1038/nrd2803 19478820 Tsvetkov A. S. Arrasate M. Barmada S. Ando D. M. Sharma P. Shaby B. A. (2013). Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration. Nat. Chem. Biol. 9 586–592. 10.1038/nchembio.1308 23873212 Tunez I. Montilla P. Del Carmen Munoz M. Feijoo M. Salcedo M. (2004). Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington’s disease. J. Pineal. Res. 37 252–256. 10.1111/j.1600-079X.2004.00163.x 15485551 Turanli B. Grotli M. Boren J. Nielsen J. Uhlen M. Arga K. Y. (2018). Drug repositioning for effective prostate cancer treatment. Front. Physiol. 9:500. 10.3389/fphys.2018.00500 Underwood B. R. Imarisio S. Fleming A. Rose C. Krishna G. Heard P. (2010). Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease. Hum. Mol. Genet. 19 3413–3429. 10.1093/hmg/ddq253 20566712 Van Raamsdonk J. M. Pearson J. Bailey C. D. Rogers D. A. Johnson G. V. Hayden M. R. (2005). Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J. Neurochem. 95 210–220. 10.1111/j.1471-4159.2005.03357.x 16181425 Varshavsky A. (1998). Codominant interference, antieffectors, and multitarget drugs. Proc. Natl. Acad. Sci. U.S.A. 95 2094–2099. 10.1073/pnas.95.5.2094 9482844 Vucetic M. Cormerais Y. Parks S. K. Pouyssegur J. (2017). The central role of amino acids in cancer redox homeostasis: vulnerability points of the cancer redox code. Front. Oncol. 7:319. 10.3389/fonc.2017.00319 29312889 Wang J. Q. Chen Q. Wang X. Wang Q. C. Wang Y. Cheng H. P. (2013). Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease. J. Biol. Chem. 288 3070–3084. 10.1074/jbc.M112.407726 23250749 Wang X. Sirianni A. Pei Z. Cormier K. Smith K. Jiang J. (2011). The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J. Neurosci. 31 14496–14507. 10.1523/JNEUROSCI.3059-11.2011 21994366 Wilson J. X. Peters C. E. Sitar S. M. Daoust P. Gelb A. W. (2000). Glutamate stimulates ascorbate transport by astrocytes. Brain Res. 858 61–66. 10.1016/S0006-8993(99)02433-6 10700597 Wondrak G. T. (2009). Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid. Redox. Signal. 11 3013–3069. 10.1089/ARS.2009.2541 19496700 Wright D. J. Gray L. J. Finkelstein D. I. Crouch P. J. Pow D. Pang T. Y. (2016). N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington’s disease. Hum. Mol. Genet. 25 2923–2933. 10.1093/hmg/ddw144 27179791 Wright D. J. Renoir T. Smith Z. M. Frazier A. E. Francis P. S. Thorburn D. R. (2015). N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington’s disease. Transl. Psychiatry 5:e492. 10.1038/tp.2014.131 25562842 Xun Z. Rivera-Sanchez S. Ayala-Pena S. Lim J. Budworth H. Skoda E. M. (2012). Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington’s disease. Cell Rep. 2 1137–1142. 10.1016/j.celrep.2012.10.001 23122961 Yang L. Calingasan N. Y. Wille E. J. Cormier K. Smith K. Ferrante R. J. (2009). Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s diseases. J. Neurochem. 109 1427–1439. 10.1111/j.1471-4159.2009.06074.x 19476553 Yin X. Manczak M. Reddy P. H. (2016). Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington’s disease. Hum. Mol. Genet. 25 1739–1753. 10.1093/hmg/ddw045 26908605